Lung cancer is the leading cause of cancer-related mortality worldwide. Elucidating the molecular programs that enable tumor cells to evade regulated cell death and anti-tumor immune responses is essential for developing effective therapeutic strategies. In this study, Wang and colleagues employ a series of genetically engineered non-small cell lung cancer mouse models, high-throughput lipidomics assays, and functional perturbation experiments to uncover how tumor cells adapt metabolically to escape ferroptosis and reprogram the tumor microenvironment for CD8⁺ T cell dysfunction.

Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Researchers at the University of Gothenburg have discovered that milk from grey seals in the Atlantic Ocean may be more potent than breast milk. An analysis of seal milk found approximately 33 per cent more sugar molecules than in breast milk. Many of these sugars are unique and may pave the way for even better infant formula for babies.   

Early-stage gastric cancer can be assessed more accurately using a new liquid biopsy tool that predicts lymph node metastasis, as reported by researchers from Science Tokyo. They developed a model that uses deoxyribonucleic acid (DNA) methylation biomarkers in plasma and computed tomography imaging to predict the risk of metastasis. This tool will help low-risk patients safely avoid unnecessary invasive surgery.

The SISAQOL-IMI consortium, co-led by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), just announced the publication of its pivotal paper in The Lancet Oncology outlining how its recommendations for patient-reported outcomes (PROs) in cancer clinical trials were developed. Alongside the publication, the consortium has released a suite of accessible online materials designed to support researchers, clinicians, regulators, and policy makers in implementing these recommendations.